Reid Merryman, MD, on Pre- and Post-Transplant Data for Patients with DLBCL

News
Video

Merryman explains the value of evaluating separate transplant-related questions for patients with relapsed or refractory diffuse large B-cell lymphoma.

Reid Merryman, MD, of the Dana-Farber Cancer Institute, spoke with CancerNetwork® about the significance of dividing cohorts of patients with diffuse large B-cell lymphoma (DLBCL) into by pre- and post-transplantation groups and the questions that need to be asked from an oral presentation at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition.

Transcription:

So, I think it’s kind of 2 different questions. Looking at samples before transplant, you’re asking, “could we use information that we have to determine if transplant is the right treatment approach for patients?” And [What’s] different from 5 or 10 years ago, I think [is that] we have novel treatments. The obvious one would be CAR [chimeric antigen receptor] T-cell therapies that could potentially be used with curative intent in this setting for patients who we think might do poorly with autologous stem cell transplant.

We’re asking a little bit of a different question for the serial samples after autologous stem cell transplant. In that setting, obviously, the patient has undergone transplantation. The question would be, “are there things that we could do in terms of maintenance or consolidation therapies that might improve outcomes for high-risk patients who are likely to relapse?”

Related Videos
Some patients with large B-cell lymphoma may have to travel a great distance for an initial evaluation for CAR T-cell therapy.
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Education is essential to referring oncologists manage toxicities associated with CAR T-cell therapy for patients with large B-cell lymphoma.
There is no absolute age cutoff where CAR T cells are contraindicated for those with large B-cell lymphoma, says David L. Porter, MD.
David L. Porter, MD, emphasizes referring patients with large B-cell lymphoma early for CAR T-cell therapy consultation.
It may be applicable to administer CAR T-cell therapy to patients with large B-cell lymphoma in a community or outpatient setting.
Findings from a study highlight that 7/8 mismatched unrelated donor posttransplant cyclophosphamide may be a suitable alternative treatment option for those with graft-vs-host disease.
Considering cystectomy in patients with bladder cancer may help with managing the shortage of Bacillus Calmette-Guerin, according to Joshua J. Meeks, MD, PhD, BS.
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.